Key result
Prolonged duration of untreated schizophrenia prior to long-acting injectable antipsychotics was associated with significantly lower global longitudinal strain and myocardial impairment.
Why the study?
To assess the cardiovascular impact of long-term injectable antipsychotics in schizophrenia spectrum disorders, evaluate potential causes of cardiovascular damage, and compare long-acting injectable olanzapine versus risperidone.
Does long-acting injectable olanzapine improve myocardial contractility compared to risperidone in patients with schizophrenia spectrum disorders?
Cross-Sectional (n=64)
Yes
Does long-acting injectable olanzapine improve myocardial contractility compared to risperidone in patients with schizophrenia spectrum disorders?
Prolonged untreated schizophrenia is associated with myocardial impairment, and olanzapine may offer better preservation of myocardial contractility compared to risperidone among long-acting injectable antipsychotics.
Cardiovascular monitoring may be prudent in long-term injectable antipsychotic users; cross-sectional data leave causality and clinical impact open.
PURPOSE: This research article assesses the cardiovascular impact of long-term injectable antipsychotic therapy on patients diagnosed with schizophrenia spectrum disorders. In our study, we attempted to quantify the potential causes of cardiovascular damage, assess cardiovascular parameters, and correlate them with the time elapsed from the onset of the psychosis until the initiation of injectable antipsychotic therapy, as well as the duration of long-acting therapy, and finally, to compare two of the most utilized long-acting injectable (LAI) medications (olanzapine vs risperidone). PATIENTS AND METHODS: This cross-sectional study recruited 64 patients of 2 outpatient clinics undergoing treatment with LAI antipsychotics for schizophrenic spectrum disorder. The study reports outpatients' clinical data, laboratory blood sample findings, routine echocardiography, as well as speckle tracking echocardiography. RESULTS: Among patients with longer durations of pre-long-acting antipsychotic treatment, body mass indices, mitral velocity wave values (E and A waves), and the global longitudinal strain (GLS) measurements significantly correlated with patients' myocardial contractility. The study also found that GLS was significantly lower in the group in which pre-LAI duration was prolonged, and was not influenced by the duration of LAI treatment. Furthermore, patients receiving olanzapine showed significantly improved myocardial contractility as measured by the aforementioned parameters, in comparison with patients treated with risperidone. CONCLUSION: The results of our study indicate that patients suffering from schizophrenia and who are left untreated or poorly treated for a longer period of time may develop myocardial impairment. The changes may be both secondary to a high prevalence of cardiovascular risk factors and may also be generated by the disease per se. The group who received olanzapine demonstrated improved results for a longer period of time without proper medication.
No takes yet. Share an insight, caveat, or question.
Andor et al. (2019) conducted a cross-sectional in schizophrenia spectrum disorders (n=64). Long-acting injectable antipsychotics (olanzapine vs risperidone) and pre-LAI duration vs. Risperidone / shorter pre-LAI duration was evaluated on Cardiovascular parameters including global longitudinal strain (GLS) and myocardial contractility. Prolonged duration of untreated schizophrenia prior to long-acting injectable antipsychotics was associated with significantly lower global longitudinal strain and myocardial impairment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: